Celltrion’s monoclonal antibody treatment for COVID-19 works against Delta variant: Study
Regdanvimab (CT-P59) also retained its neutralisation potency against the Lambda variant (C.37, first identified in Peru) using a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Celltrion Group
Celltrion develops neutralising antibody cocktail to tackle COVID-19 variant spread
CT-P59 demonstrated neutralising capability against key emerging mutations, including the UK variant in addition to six variant…
Celltrion concludes enrolment for Phase II clinical trial of COVID-19 monoclonal treatment
Celltrion anticipates submission for EUA to the Korean Ministry of Food and Drug Safety (MFDS), conditional on results from the…